CN1634482A - 红花滴丸及其制备方法 - Google Patents
红花滴丸及其制备方法 Download PDFInfo
- Publication number
- CN1634482A CN1634482A CN 200410096326 CN200410096326A CN1634482A CN 1634482 A CN1634482 A CN 1634482A CN 200410096326 CN200410096326 CN 200410096326 CN 200410096326 A CN200410096326 A CN 200410096326A CN 1634482 A CN1634482 A CN 1634482A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- drug extract
- safflower
- substrate
- mixed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006187 pill Substances 0.000 title claims abstract description 62
- 244000020518 Carthamus tinctorius Species 0.000 title claims abstract description 36
- 235000003255 Carthamus tinctorius Nutrition 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 126
- 238000000034 method Methods 0.000 claims abstract description 31
- 206010047115 Vasculitis Diseases 0.000 claims abstract description 8
- 208000029078 coronary artery disease Diseases 0.000 claims abstract description 8
- 208000019553 vascular disease Diseases 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims description 96
- 239000002202 Polyethylene glycol Substances 0.000 claims description 91
- 229920001223 polyethylene glycol Polymers 0.000 claims description 91
- 239000000284 extract Substances 0.000 claims description 86
- 239000000758 substrate Substances 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- -1 polyoxyethylene stearate Polymers 0.000 claims description 37
- 229920002472 Starch Polymers 0.000 claims description 35
- 239000008107 starch Substances 0.000 claims description 35
- 235000019698 starch Nutrition 0.000 claims description 35
- 229920000858 Cyclodextrin Polymers 0.000 claims description 32
- 239000001116 FEMA 4028 Substances 0.000 claims description 32
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 32
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 32
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 32
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 32
- 229960004853 betadex Drugs 0.000 claims description 32
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 32
- 229920001983 poloxamer Polymers 0.000 claims description 32
- 229960000502 poloxamer Drugs 0.000 claims description 32
- 239000011734 sodium Substances 0.000 claims description 32
- 229910052708 sodium Inorganic materials 0.000 claims description 32
- 150000002148 esters Chemical class 0.000 claims description 31
- 241000628997 Flos Species 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 12
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 11
- 239000001828 Gelatine Substances 0.000 claims description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 10
- 235000021355 Stearic acid Nutrition 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 10
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 10
- 239000008117 stearic acid Substances 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 8
- 238000004064 recycling Methods 0.000 claims description 8
- 230000002490 cerebral effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 235000015424 sodium Nutrition 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 3
- 230000005494 condensation Effects 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000009413 insulation Methods 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- 229920002545 silicone oil Polymers 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 238000007493 shaping process Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 231100001231 less toxic Toxicity 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 description 53
- 238000012360 testing method Methods 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 14
- 229940090044 injection Drugs 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000000969 carrier Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000004353 Polyethylene glycol 8000 Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000470 constituent Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 235000015250 liver sausages Nutrition 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 241001640034 Heteropterys Species 0.000 description 1
- 244000208060 Lawsonia inermis Species 0.000 description 1
- YYSRTHIUABRSAB-UHFFFAOYSA-N Neocarthamin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C(O)C2=C1C(=O)CC(C=1C=CC(O)=CC=1)O2 YYSRTHIUABRSAB-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002304 glucoses Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- UBFTZAGDGOMJQE-SACPXRHSSA-N neocarthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(O)C(O)=CC2=C1C(=O)C[C@@H](C=1C=CC(O)=CC=1)O2 UBFTZAGDGOMJQE-SACPXRHSSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000000246 remedial effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
聚乙二醇2000 | 50.0 | 62 | <30 | >10 | + |
聚乙二醇4000 | 50.0 | 77 | <30 | >10 | ++ |
聚乙二醇6000 | 50.0 | 81 | <30 | >10 | +++ |
聚乙二醇8000 | 50.0 | 83 | <30 | >10 | +++ |
聚乙二醇10000 | 50.0 | 87 | <30 | <10 | +++ |
聚乙二醇20000 | 50.0 | 86 | <30 | <10 | +++ |
硬脂酸聚烃氧40酯 | 50.0 | 75 | <30 | >10 | ++ |
倍他环糊精 | 50.0 | 70 | <30 | >10 | ++ |
泊洛沙姆 | 50.0 | 71 | <30 | >10 | ++ |
羧甲基淀粉钠 | 50.0 | 71 | <30 | >10 | ++ |
十二烷基硫酸钠 | 50.0 | 69 | <30 | >10 | ++ |
硬脂酸 | 50.0 | 54 | <30 | >10 | ++ |
硬脂酸钠 | 50.0 | 54 | <30 | >10 | +++ |
甘油明胶 | 50.0 | 55 | <30 | >10 | +++ |
虫胶 | 50.0 | 51 | >30 | >10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
聚乙二醇2000 | 25.0 | 78 | <30 | >10 | ++ |
聚乙二醇4000 | 25.0 | 85 | <30 | <10 | +++ |
聚乙二醇6000 | 25.0 | 91 | <30 | <10 | +++ |
聚乙二醇8000 | 25.0 | 90 | <30 | <10 | +++ |
聚乙二醇10000 | 25.0 | 93 | <30 | <10 | +++ |
聚乙二醇20000 | 25.0 | 92 | <30 | <10 | +++ |
硬脂酸聚烃氧40酯 | 25.0 | 86 | <30 | <10 | ++ |
倍他环糊精 | 25.0 | 82 | <30 | <10 | ++ |
泊洛沙姆 | 25.0 | 85 | <30 | <10 | +++ |
羧甲基淀粉钠 | 25.0 | 81 | <30 | >10 | ++ |
十二烷基硫酸钠 | 25.0 | 76 | <30 | >10 | ++ |
硬脂酸 | 25.0 | 72 | >30 | >10 | ++ |
硬脂酸钠 | 25.0 | 73 | >30 | >10 | +++ |
甘油明胶 | 25.0 | 68 | >30 | >10 | +++ |
虫胶 | 25.0 | 69 | >30 | >10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
聚乙二醇2000 | 10.0 | 83 | <30 | >10 | ++ |
聚乙二醇4000 | 10.0 | 88 | <30 | <10 | +++ |
聚乙二醇6000 | 10.0 | 92 | <30 | <10 | +++ |
聚乙二醇8000 | 10.0 | 93 | <30 | <10 | +++ |
聚乙二醇10000 | 10.0 | 93 | <30 | <10 | +++ |
聚乙二醇20000 | 10.0 | 94 | <30 | <10 | +++ |
硬脂酸聚烃氧40酯 | 10.0 | 89 | <30 | <10 | ++ |
倍他环糊精 | 10.0 | 87 | <30 | <10 | ++ |
泊洛沙姆 | 10.0 | 92 | <30 | <10 | +++ |
羧甲基淀粉钠 | 10.0 | 82 | <30 | >10 | +++ |
十二烷基硫酸钠 | 10.0 | 81 | <30 | >10 | +++ |
硬脂酸 | 10.0 | 79 | >30 | >10 | +++ |
硬脂酸钠 | 10.0 | 80 | >30 | >10 | +++ |
甘油明胶 | 10.0 | 74 | >30 | >10 | +++ |
虫胶 | 10.0 | 77 | >30 | >10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶1 | 50 | 83 | <30 | >10 | ++ |
泊洛沙姆∶聚乙二醇=1∶1 | 50 | 82 | <30 | >10 | ++ |
羧甲基淀粉钠∶聚乙二醇=1∶1 | 50 | 77 | <30 | >10 | ++ |
倍他环糊精∶聚乙二醇=1∶1 | 50 | 73 | <30 | >10 | + |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶1 | 25 | 87 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶1 | 25 | 88 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶1 | 25 | 83 | <30 | >10 | ++ |
倍他环糊精∶聚乙二醇=1∶1 | 25 | 81 | <30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶1 | 10 | 88 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶1 | 10 | 86 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶1 | 10 | 84 | <30 | >10 | +++ |
倍他环糊精∶聚乙二醇=1∶1 | 10 | 82 | <30 | >10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶5 | 50 | 91 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶5 | 50 | 93 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶5 | 50 | 87 | <30 | <10 | +++ |
倍他环糊精∶聚乙二醇=1∶5 | 50 | 83 | <30 | >10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶5 | 25 | 92 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶5 | 25 | 91 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶5 | 25 | 89 | <30 | <10 | +++ |
倍他环糊精∶聚乙二醇=1∶5 | 25 | 87 | <30 | <10 | ++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶5 | 10 | 94 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶5 | 10 | 93 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶5 | 10 | 91 | <30 | <10 | +++ |
倍他环糊精∶聚乙二醇=1∶5 | 10 | 89 | <30 | <10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶10 | 50 | 92 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶10 | 50 | 91 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶10 | 50 | 87 | <30 | <10 | +++ |
倍他环糊精∶聚乙二醇=1∶10 | 50 | 85 | <30 | >10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶10 | 25 | 91 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶10 | 25 | 92 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶10 | 25 | 89 | <30 | <10 | +++ |
倍他环糊精∶聚乙二醇=1∶10 | 25 | 86 | <30 | <10 | +++ |
基质名称 | 有效成分(%) | 圆整率(%) | 溶散时限(分钟) | 丸重差异(%) | 硬度 |
硬脂酸聚烃氧40酯∶聚乙二醇=1∶10 | 10 | 91 | <30 | <10 | +++ |
泊洛沙姆∶聚乙二醇=1∶10 | 10 | 92 | <30 | <10 | +++ |
羧甲基淀粉钠∶聚乙二醇=1∶10 | 10 | 91 | <30 | <10 | +++ |
倍他环糊精∶聚乙二醇=1∶10 | 10 | 92 | <30 | <10 | +++ |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100963265A CN1307975C (zh) | 2004-11-30 | 2004-11-30 | 红花滴丸及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100963265A CN1307975C (zh) | 2004-11-30 | 2004-11-30 | 红花滴丸及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634482A true CN1634482A (zh) | 2005-07-06 |
CN1307975C CN1307975C (zh) | 2007-04-04 |
Family
ID=34847852
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100963265A Expired - Fee Related CN1307975C (zh) | 2004-11-30 | 2004-11-30 | 红花滴丸及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1307975C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687282A (zh) * | 2015-12-17 | 2016-06-22 | 北京大学 | 红花抗帕金森病有效部位滴丸及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1048897C (zh) * | 1995-03-08 | 2000-02-02 | 鲁洪艺 | 治疗冠心病、心绞痛、心肌梗塞的中成药及其制备方法 |
-
2004
- 2004-11-30 CN CNB2004100963265A patent/CN1307975C/zh not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105687282A (zh) * | 2015-12-17 | 2016-06-22 | 北京大学 | 红花抗帕金森病有效部位滴丸及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1307975C (zh) | 2007-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1679676A (zh) | 六味西红花滴丸及其制备方法 | |
CN1686389A (zh) | 一种以丹参、红花制备而成的丹红滴丸及其制备方法 | |
CN1634476A (zh) | 麻杏止咳滴丸及其制备方法 | |
CN1307975C (zh) | 红花滴丸及其制备方法 | |
CN1634509A (zh) | 一种治疗疼痛的伊痛舒滴丸及其制备方法 | |
CN1297254C (zh) | 熊胆川贝滴丸及其制备方法 | |
CN1634508A (zh) | 雪莲滴丸及其制备方法 | |
CN1679673A (zh) | 板蓝根滴丸及其制备方法 | |
CN1316958C (zh) | 丁公藤滴丸及其制备方法 | |
CN1686384A (zh) | 一种治疗心脏病的冠心宁滴丸及其制备方法 | |
CN1686388A (zh) | 一种治疗肿瘤、乙肝的康艾滴丸及其制备方法 | |
CN1316957C (zh) | 穿山龙滴丸及其制备方法 | |
CN1307976C (zh) | 一种用于治疗心脏病的舒胸滴丸及其制备方法 | |
CN1679677A (zh) | 一种具有活血化瘀作用的丹七滴丸及其制备方法 | |
CN1301107C (zh) | 以穿心莲内酯磺化物制备而成的滴丸及其制备方法 | |
CN1634511A (zh) | 一种治疗风湿病的风湿宁滴丸及其制备方法 | |
CN1634452A (zh) | 养阴清肺滴丸 | |
CN1686432A (zh) | 地龙滴丸及其制备方法 | |
CN1686385A (zh) | 复方麝香滴丸及其制备方法 | |
CN1297256C (zh) | 一种用于治疗冠心病的口服滴丸制剂及其制备方法 | |
CN1634145A (zh) | 一种治疗脑炎、肝昏迷的醒脑静滴丸及其制备方法 | |
CN1301094C (zh) | 一种治疗口腔疾病的喉痛消炎滴丸及其制备方法 | |
CN1698833A (zh) | 复方苦参滴丸及其制备方法 | |
CN1686387A (zh) | 一种治疗癌症疼痛的乌头滴丸及其制备方法 | |
CN1682818A (zh) | 灯盏地龙滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG CHINA WO MEDICINE CO. Free format text: FORMER OWNER: ZHENGDA-LUZHOU MEDICINE SCIENCE-TECHNOLOGY CO., LTD., BEIJING Effective date: 20080530 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080530 Address after: No. 2900, Shengli Road, West Street, Shandong, Weifang Patentee after: Wohua Medicine Science and Technology Co., Ltd., Shandong Address before: Beijing economic and Technological Development Zone Hongda North Road, 12 innovation building, block B, two, 201 Patentee before: Beijing Zhengda Oasis Medicine Technology Co., Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Wohua Medicine Science and Technology Co., Ltd., Shandong Document name: Notification to Pay the Fees |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Zhou Wanhui Document name: Notification of Termination of Patent Right |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070404 Termination date: 20191130 |